| Year |
Citation |
Score |
| 2022 |
Koubek EJ, Weissenrieder JS, Ortiz LE, Nwogu N, Pham AM, Weissenkampen JD, Reed JL, Neighbors JD, Hohl RJ, Kwun HJ. Therapeutic Potential of 5'-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma. Viruses. 14. PMID 36146655 DOI: 10.3390/v14091848 |
0.303 |
|
| 2019 |
Larson-Casey JL, Vaid M, Gu L, He C, Cai GQ, Ding Q, Davis D, Berryhill TF, Wilson LS, Barnes S, Neighbors JD, Hohl RJ, Zimmerman KA, Yoder BK, Longhini ALF, et al. Increased flux through the mevalonate pathway mediates fibrotic repair without injury. The Journal of Clinical Investigation. PMID 31609245 DOI: 10.1172/Jci127959 |
0.302 |
|
| 2019 |
Kokolus KM, Haley JS, Koubek EJ, Gowda R, Dinavahi SS, Sharma A, Claxton DF, Helm KF, Drabick JJ, Robertson GP, Neighbors JD, Hohl RJ, Schell TD. Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. Oncoimmunology. 8: e1539614. PMID 30713799 DOI: 10.1080/2162402X.2018.1539614 |
0.316 |
|
| 2018 |
Koubek EJ, Weissenrieder JS, Neighbors JD, Hohl RJ. Schweinfurthins: Lipid Modulators with Promising Anticancer Activity. Lipids. PMID 30334267 DOI: 10.1002/Lipd.12088 |
0.408 |
|
| 2018 |
Wang L, Jia B, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Khawaja MR, Sivik J, Han J, Hohl RJ, Zheng H. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. Oncoimmunology. 7: e1469594. PMID 30228937 DOI: 10.1080/2162402X.2018.1469594 |
0.353 |
|
| 2018 |
Weissenrieder JS, Reilly JE, Neighbors JD, Hohl RJ. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models. The Prostate. PMID 30106164 DOI: 10.1002/Pros.23707 |
0.688 |
|
| 2018 |
Jia B, Zhao C, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Songdej N, Khawaja M, Hohl RJ, Zheng H. TIGIT Expression Positively Associates with NK Cell Function in AML Patients Blood. 132: 5250-5250. DOI: 10.1182/Blood-2018-99-113578 |
0.328 |
|
| 2017 |
Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. Journal of Hematology & Oncology. 10: 124. PMID 28629373 DOI: 10.1186/S13045-017-0486-Z |
0.304 |
|
| 2017 |
Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, ... ... Hohl RJ, et al. O2(⋅-) and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. PMID 28366679 DOI: 10.1016/J.Ccell.2017.02.018 |
0.348 |
|
| 2016 |
Reilly JE, Neighbors JD, Hohl RJ. Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis. Cancer Biology & Therapy. 0. PMID 27624889 DOI: 10.1080/15384047.2016.1219817 |
0.697 |
|
| 2015 |
Kuder CH, Weivoda MM, Zhang Y, Zhu J, Neighbors JD, Wiemer DF, Hohl RJ. 3-Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines. Lipids. PMID 26494560 DOI: 10.1007/S11745-015-4083-Z |
0.779 |
|
| 2015 |
Reilly JE, Neighbors JD, Tong H, Henry MD, Hohl RJ. Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. Clinical & Experimental Metastasis. 32: 555-66. PMID 26070429 DOI: 10.1007/S10585-015-9727-0 |
0.694 |
|
| 2015 |
Sheehy RM, Kuder CH, Bachman Z, Hohl RJ. Calcium and P-glycoprotein independent synergism between schweinfurthins and verapamil. Cancer Biology & Therapy. 16: 1259-68. PMID 26046259 DOI: 10.1080/15384047.2015.1056420 |
0.77 |
|
| 2015 |
Reilly JE, Zhou X, Tong H, Kuder CH, Wiemer DF, Hohl RJ. In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors. Biochemical Pharmacology. 96: 83-92. PMID 25952057 DOI: 10.1016/J.Bcp.2015.04.009 |
0.789 |
|
| 2014 |
Zhou X, Reilly JE, Loerch KA, Hohl RJ, Wiemer DF. Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase. Beilstein Journal of Organic Chemistry. 10: 1645-50. PMID 25161722 DOI: 10.3762/Bjoc.10.171 |
0.692 |
|
| 2014 |
Sheehy RM, Bachman ZC, Hohl RJ. Abstract 811: Schweinfurthin activity enhanced by verapamil Cancer Research. 74: 811-811. DOI: 10.1158/1538-7445.Am2014-811 |
0.401 |
|
| 2014 |
Reilly JE, Neighbors JD, Bannick N, Henry MD, Kuder CH, Hohl RJ. Abstract 4032: Targeting the isoprenoid biosynthetic pathway in a murine model of metastatic prostate cancer Cancer Research. 74: 4032-4032. DOI: 10.1158/1538-7445.Am2014-4032 |
0.769 |
|
| 2013 |
Tong H, Kuder CH, Wasko BM, Hohl RJ. Quantitative determination of isopentenyl diphosphate in cultured mammalian cells. Analytical Biochemistry. 433: 36-42. PMID 23000003 DOI: 10.1016/J.Ab.2012.09.001 |
0.771 |
|
| 2013 |
Bhasin N, Stevens J, Niki M, Tong H, Kuder C, Hohl RJ, Lentz SR. Dissecting The Effects Of Isoprenoid Pathway Inhibition On Hemostasis and Thrombosis: Differential Effects Of Atorvastatin and Digeranyl Bisphosphonate In Hypercholesterolemic Mice Blood. 122: 2378-2378. DOI: 10.1182/Blood.V122.21.2378.2378 |
0.739 |
|
| 2012 |
Holstein SA, Hohl RJ. Is there a future for prenyltransferase inhibitors in cancer therapy? Current Opinion in Pharmacology. 12: 704-9. PMID 22817869 DOI: 10.1016/J.Coph.2012.06.013 |
0.325 |
|
| 2012 |
Kuder CH, Sheehy RM, Neighbors JD, Wiemer DF, Hohl RJ. Functional evaluation of a fluorescent schweinfurthin: mechanism of cytotoxicity and intracellular quantification. Molecular Pharmacology. 82: 9-16. PMID 22461663 DOI: 10.1124/Mol.111.077107 |
0.792 |
|
| 2012 |
Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, ... ... Hohl R, et al. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prevention Research (Philadelphia, Pa.). 5: 621-30. PMID 22293631 DOI: 10.1158/1940-6207.Capr-11-0455 |
0.327 |
|
| 2012 |
Weivoda MM, Hohl RJ. Geranylgeranyl pyrophosphate stimulates PPARγ expression and adipogenesis through the inhibition of osteoblast differentiation. Bone. 50: 467-76. PMID 22019459 DOI: 10.1016/J.Bone.2011.09.056 |
0.721 |
|
| 2011 |
Wiemer AJ, Wiemer DF, Hohl RJ. Geranylgeranyl diphosphate synthase: an emerging therapeutic target. Clinical Pharmacology and Therapeutics. 90: 804-12. PMID 22048229 DOI: 10.1038/Clpt.2011.215 |
0.647 |
|
| 2011 |
Wasko BM, Smits JP, Shull LW, Wiemer DF, Hohl RJ. A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro. Journal of Lipid Research. 52: 1957-64. PMID 21903868 DOI: 10.1194/Jlr.M016089 |
0.443 |
|
| 2011 |
Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, ... ... Hohl R, et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 118: 4882-9. PMID 21725056 DOI: 10.1182/Blood-2011-02-334904 |
0.312 |
|
| 2011 |
Holstein SA, Kuder CH, Tong H, Hohl RJ. Pleiotropic effects of a schweinfurthin on isoprenoid homeostasis. Lipids. 46: 907-21. PMID 21633866 DOI: 10.1007/S11745-011-3572-Y |
0.794 |
|
| 2011 |
Weivoda MM, Hohl RJ. Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation. Endocrinology. 152: 3113-22. PMID 21586555 DOI: 10.1210/En.2011-0016 |
0.727 |
|
| 2011 |
Weivoda MM, Hohl RJ. The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation. Journal of Cellular Biochemistry. 112: 1506-13. PMID 21503955 DOI: 10.1002/Jcb.23087 |
0.723 |
|
| 2011 |
Wasko BM, Dudakovic A, Hohl RJ. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. The Journal of Pharmacology and Experimental Therapeutics. 337: 540-6. PMID 21335425 DOI: 10.1124/Jpet.110.175521 |
0.66 |
|
| 2011 |
Holstein SA, Hohl RJ. Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leukemia Research. 35: 551-9. PMID 20828814 DOI: 10.1016/J.Leukres.2010.08.008 |
0.424 |
|
| 2011 |
Dandamudi UB, Adams LM, Johnson B, Bauman J, Morris S, Murray S, Webb RT, Gartner E, Hohl R, Lewis LD. Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer Cancer Chemotherapy and Pharmacology. 67: 783-790. PMID 20556613 DOI: 10.1007/S00280-010-1381-2 |
0.326 |
|
| 2011 |
Dudakovic A, Tong H, Hohl RJ. Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration. Investigational New Drugs. 29: 912-20. PMID 20480384 DOI: 10.1007/S10637-010-9446-Y |
0.684 |
|
| 2011 |
Holstein SA, Hohl RJ. Inhibition of Farnesyl and Geranylgeranyl Diphosphate Synthases Enzymes. 30: 301-319. DOI: 10.1016/B978-0-12-415922-8.00013-6 |
0.391 |
|
| 2010 |
Ulrich NC, Kuder CH, Hohl RJ, Wiemer DF. Biologically active biotin derivatives of schweinfurthin F. Bioorganic & Medicinal Chemistry Letters. 20: 6716-20. PMID 20869871 DOI: 10.1016/J.Bmcl.2010.08.143 |
0.762 |
|
| 2010 |
Barney RJ, Wasko BM, Dudakovic A, Hohl RJ, Wiemer DF. Synthesis and biological evaluation of a series of aromatic bisphosphonates. Bioorganic & Medicinal Chemistry. 18: 7212-20. PMID 20832326 DOI: 10.1016/J.Bmc.2010.08.036 |
0.66 |
|
| 2010 |
Topczewski JJ, Kuder CH, Neighbors JD, Hohl RJ, Wiemer DF. Fluorescent schweinfurthin B and F analogs with anti-proliferative activity. Bioorganic & Medicinal Chemistry. 18: 6734-41. PMID 20724169 DOI: 10.1016/J.Bmc.2010.07.056 |
0.779 |
|
| 2010 |
Ulrich NC, Kodet JG, Mente NR, Kuder CH, Beutler JA, Hohl RJ, Wiemer DF. Structural analogues of schweinfurthin F: probing the steric, electronic, and hydrophobic properties of the D-ring substructure. Bioorganic & Medicinal Chemistry. 18: 1676-83. PMID 20116262 DOI: 10.1016/J.Bmc.2009.12.063 |
0.773 |
|
| 2010 |
Holstein SA, Tong H, Hohl RJ. Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leukemia Research. 34: 344-51. PMID 19646757 DOI: 10.1016/J.Leukres.2009.06.035 |
0.431 |
|
| 2010 |
Witzig TE, Hui T, Micallef IN, Ansell SM, Link B, Inwards DJ, Porrata L, Johnston PB, Colgan J, Markovic S, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Weiner G, ... Hohl RJ, et al. A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas Blood. 116: 287-287. DOI: 10.1182/Blood.V116.21.287.287 |
0.319 |
|
| 2009 |
Holstein SA, Tong H, Kuder CH, Hohl RJ. Quantitative determination of geranyl diphosphate levels in cultured human cells. Lipids. 44: 1055-62. PMID 19856009 DOI: 10.1007/S11745-009-3355-X |
0.791 |
|
| 2009 |
Wiemer AJ, Hohl RJ, Wiemer DF. The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anti-Cancer Agents in Medicinal Chemistry. 9: 526-42. PMID 19519294 DOI: 10.2174/187152009788451860 |
0.712 |
|
| 2009 |
Kuder CH, Neighbors JD, Hohl RJ, Wiemer DF. Synthesis and biological activity of a fluorescent schweinfurthin analogue. Bioorganic & Medicinal Chemistry. 17: 4718-23. PMID 19464190 DOI: 10.1016/J.Bmc.2009.04.071 |
0.78 |
|
| 2009 |
Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jagannath S. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leukemia & Lymphoma. 50: 559-65. PMID 19373653 DOI: 10.1080/10428190902748971 |
0.302 |
|
| 2008 |
Tong H, Wiemer AJ, Neighbors JD, Hohl RJ. Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue. Analytical Biochemistry. 378: 138-43. PMID 18457649 DOI: 10.1016/J.Ab.2008.04.021 |
0.63 |
|
| 2008 |
Wiemer AJ, Yu JS, Shull LW, Barney RJ, Wasko BM, Lamb KM, Hohl RJ, Wiemer DF. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation. Bioorganic & Medicinal Chemistry. 16: 3652-60. PMID 18308574 DOI: 10.1016/J.Bmc.2008.02.016 |
0.715 |
|
| 2008 |
Dudakovic A, Wiemer AJ, Lamb KM, Vonnahme LA, Dietz SE, Hohl RJ. Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes. The Journal of Pharmacology and Experimental Therapeutics. 324: 1028-36. PMID 18083912 DOI: 10.1124/Jpet.107.132217 |
0.781 |
|
| 2008 |
Hamadmad SN, Hohl RJ. Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. The Journal of Pharmacology and Experimental Therapeutics. 324: 1227-33. PMID 18079357 DOI: 10.1124/Jpet.107.129643 |
0.799 |
|
| 2008 |
Wiemer AJ, Yu JS, Lamb KM, Hohl RJ, Wiemer DF. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorganic & Medicinal Chemistry. 16: 390-9. PMID 17905588 DOI: 10.1016/J.Bmc.2007.09.029 |
0.708 |
|
| 2008 |
Holstein SA, Tong H, Hohl RJ. Biochemical Basis for Interactions Between Thalidomide and Inhibitors of the Isoprenoid Biosynthetic Pathway in Multiple Myeloma Cells Blood. 112: 2635-2635. DOI: 10.1182/Blood.V112.11.2635.2635 |
0.455 |
|
| 2007 |
Hamadmad SN, Hohl RJ. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. Biochemical Pharmacology. 74: 590-600. PMID 17586475 DOI: 10.1016/J.Bcp.2007.04.028 |
0.802 |
|
| 2007 |
Maalouf MA, Wiemer AJ, Kuder CH, Hohl RJ, Wiemer DF. Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation. Bioorganic & Medicinal Chemistry. 15: 1959-66. PMID 17254791 DOI: 10.1016/J.Bmc.2007.01.002 |
0.787 |
|
| 2007 |
Mente NR, Wiemer AJ, Neighbors JD, Beutler JA, Hohl RJ, Wiemer DF. Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: differences of bioactivity in the enantiomeric series. Bioorganic & Medicinal Chemistry Letters. 17: 911-5. PMID 17236766 DOI: 10.1016/J.Bmcl.2006.11.096 |
0.596 |
|
| 2007 |
Wiemer AJ, Tong H, Swanson KM, Hohl RJ. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochemical and Biophysical Research Communications. 353: 921-5. PMID 17208200 DOI: 10.1016/J.Bbrc.2006.12.094 |
0.706 |
|
| 2006 |
Shull LW, Wiemer AJ, Hohl RJ, Wiemer DF. Synthesis and biological activity of isoprenoid bisphosphonates. Bioorganic & Medicinal Chemistry. 14: 4130-6. PMID 16517172 DOI: 10.1016/J.Bmc.2006.02.010 |
0.691 |
|
| 2006 |
Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate pathway. Current Cancer Drug Targets. 6: 15-37. PMID 16475974 DOI: 10.2174/156800906775471743 |
0.421 |
|
| 2006 |
Hamadmad SN, Henry MK, Hohl RJ. Erythropoietin receptor signal transduction requires protein geranylgeranylation. The Journal of Pharmacology and Experimental Therapeutics. 316: 403-9. PMID 16203826 DOI: 10.1124/Jpet.105.092510 |
0.789 |
|
| 2006 |
Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemotherapy and Pharmacology. 57: 155-64. PMID 16133537 DOI: 10.1007/S00280-005-0013-8 |
0.313 |
|
| 2006 |
Askeland EJ, Wiemer AJ, Hohl RJ. Synergism between Anti-Leukemia Therapeutics and Isoprenoid Pathway Inhibitors in K562 Leukemia Cells. Blood. 108: 4815-4815. DOI: 10.1182/Blood.V108.11.4815.4815 |
0.71 |
|
| 2005 |
Murthy S, Tong H, Hohl RJ. Regulation of fatty acid synthesis by farnesyl pyrophosphate. The Journal of Biological Chemistry. 280: 41793-804. PMID 16221687 DOI: 10.1074/Jbc.M504101200 |
0.354 |
|
| 2005 |
Lewis KA, Holstein SA, Hohl RJ. Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leukemia Research. 29: 527-33. PMID 15755505 DOI: 10.1016/J.Leukres.2004.10.007 |
0.371 |
|
| 2005 |
Tong H, Holstein SA, Hohl RJ. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Analytical Biochemistry. 336: 51-9. PMID 15582558 DOI: 10.1016/J.Ab.2004.09.024 |
0.372 |
|
| 2005 |
Swanson KM, Tong H, Wiemer AJ, Murthy S, Hohl RJ. Potential mechanisms for the anti-myeloma properties of bisphosphonates Journal of Clinical Oncology. 23: 6586-6586. DOI: 10.1200/Jco.2005.23.16_Suppl.6586 |
0.705 |
|
| 2004 |
Kim M, Kleckley TS, Wiemer AJ, Holstein SA, Hohl RJ, Wiemer DF. Synthesis and activity of fluorescent isoprenoid pyrophosphate analogues. The Journal of Organic Chemistry. 69: 8186-93. PMID 15549786 DOI: 10.1021/Jo049101W |
0.681 |
|
| 2004 |
Holstein SA, Hohl RJ. Isoprenoids: remarkable diversity of form and function. Lipids. 39: 293-309. PMID 15357017 DOI: 10.1007/S11745-004-1233-3 |
0.324 |
|
| 2004 |
Henry MK, Nimbalkar D, Hohl RJ, Quelle FW. Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells. Experimental Cell Research. 299: 257-66. PMID 15302592 DOI: 10.1016/J.Yexcr.2004.06.003 |
0.397 |
|
| 2004 |
Swanson KM, Wiemer AJ, Hohl RJ. Bisphosphonates Influence Isoprenylation of Small Gtpases in Human Myeloma Cells. Blood. 104: 3401-3401. DOI: 10.1182/Blood.V104.11.3401.3401 |
0.706 |
|
| 2004 |
Sbaity SA, Murthy S, Romig S, Hohl R, Weintraub N, Stoll L. 1122-169 Statins block endotoxin-induced proinflammatory responses in human coronary artery cells by inhibition of Rho protein-mediated signaling Journal of the American College of Cardiology. 43: A498. DOI: 10.1016/S0735-1097(04)92108-0 |
0.323 |
|
| 2003 |
Ownby SE, Hohl RJ. Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis. Lipids. 38: 751-9. PMID 14506838 DOI: 10.1007/S11745-003-1123-8 |
0.781 |
|
| 2003 |
Holstein SA, Wohlford-Lenane CL, Wiemer DF, Hohl RJ. Isoprenoid pyrophosphate analogues regulate expression of Ras-related proteins. Biochemistry. 42: 4384-91. PMID 12693933 DOI: 10.1021/Bi027227M |
0.359 |
|
| 2003 |
Holstein SA, Hohl RJ. Monoterpene regulation of Ras and Ras-related protein expression. Journal of Lipid Research. 44: 1209-15. PMID 12671036 DOI: 10.1194/Jlr.M300057-Jlr200 |
0.349 |
|
| 2002 |
Chen X, Wiemer AJ, Hohl RJ, Wiemer DF. Stereoselective synthesis of the 5'-hydroxy-5'-phosphonate derivatives of cytidine and cytosine arabinoside. The Journal of Organic Chemistry. 67: 9331-9. PMID 12492335 DOI: 10.1021/Jo020483K |
0.649 |
|
| 2002 |
Holstein SA, Wohlford-Lenane CL, Hohl RJ. Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry. 41: 13698-704. PMID 12427032 DOI: 10.1021/Bi026251X |
0.322 |
|
| 2002 |
Ownby SE, Hohl RJ. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells. Lipids. 37: 185-92. PMID 11908910 DOI: 10.1007/S11745-002-0879-1 |
0.789 |
|
| 2002 |
Holstein SA, Wohlford-Lenane CL, Hohl RJ. Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB. The Journal of Biological Chemistry. 277: 10678-82. PMID 11788600 DOI: 10.1074/Jbc.M111369200 |
0.32 |
|
| 2002 |
Chen X, Jung KY, Wiemer DF, Wiemer AJ, Hohl RJ. Phosphonate analogues of cytosine arabinoside monophosphate Phosphorus, Sulfur and Silicon and Related Elements. 177: 1783-1786. DOI: 10.1080/10426500212248 |
0.656 |
|
| 2001 |
Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells Molecular Cancer Therapeutics. 1: 141-149. PMID 12467231 |
0.316 |
|
| 2001 |
Holstein SA, Hohl RJ. Interaction of cytosine arabinoside and lovastatin in human leukemia cells Leukemia Research. 25: 651-660. PMID 11397469 DOI: 10.1016/S0145-2126(00)00162-4 |
0.354 |
|
| 2000 |
Cermak DM, Wiemer DF, Lewis K, Hohl RJ. 2-(Acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: synthesis and biological characterization Bioorganic and Medicinal Chemistry. 8: 2729-2737. PMID 11131164 DOI: 10.1016/S0968-0896(00)00212-1 |
0.377 |
|
| 2000 |
Jung KY, Hohl RJ, Wiemer AJ, Wiemer DF. Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside. Bioorganic & Medicinal Chemistry. 8: 2501-9. PMID 11058045 DOI: 10.1016/S0968-0896(00)00183-8 |
0.658 |
|
| 1998 |
Holstein SA, Cermak DM, Wiemer DF, Lewis K, Hohl RJ. Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase Bioorganic and Medicinal Chemistry. 6: 687-694. PMID 9681134 DOI: 10.1016/S0968-0896(98)00034-0 |
0.363 |
|
| 1998 |
Hohl RJ, Lewis KA, Cermak DM, Wiemer DF. Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids Lipids. 33: 39-46. PMID 9470172 DOI: 10.1007/S11745-998-0178-X |
0.346 |
|
| 1996 |
Goldman F, Hohl RJ, Crabtree J, Lewis-Tibesar K, Koretzky G. Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras Blood. 88: 4611-4619. PMID 8977253 DOI: 10.1182/Blood.V88.12.4611.Bloodjournal88124611 |
0.382 |
|
| 1996 |
Hohl RJ. Monoterpenes as regulators of malignant cell proliferation Advances in Experimental Medicine and Biology. 401: 137-146. PMID 8886132 DOI: 10.1007/978-1-4613-0399-2_11 |
0.344 |
|
| 1995 |
Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing Journal of Biological Chemistry. 270: 17508-17512. PMID 7615555 DOI: 10.1074/Jbc.270.29.17508 |
0.325 |
|
| 1991 |
Hohl RJ, Larson RA, Mannickarottu V, Yachnin S. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells Blood. 77: 1064-1070. PMID 1995091 DOI: 10.1182/Blood.V77.5.1064.Bloodjournal7751064 |
0.358 |
|
| Show low-probability matches. |